On September 16, 2026, the CPHI Shenzhen 2026 Pharmaceutical High-Quality Development Conference-held in conjunction with the 5th International Symposium on Natural Product Synthesis and Advanced Pharmaceutical Manufacturing Methods-officially kicked off at the Shenzhen Convention & Exhibition Center (Futian). As a premier annual event for the pharmaceutical industry in South China, this conference leverages the platform of the CPHI & PMEC Shenzhen Pharmaceutical Industry Exhibition. It focuses on key sectors such as API innovation and upgrading, the evolution of high-end formulation technologies, and cutting-edge applications in synthetic biology. Bringing together over a hundred top industry experts, researchers, and corporate leaders, the event delivers high-value insights on frontier technologies, regulatory compliance, and innovative R&D, establishing an efficient platform for exchange and practical implementation to drive the high-quality, intelligent, and green development of the pharmaceutical industry in the Greater Bay Area and across the nation.
Organized by Sinoexpo Informa Markets and co-created by the Shenzhen Pingshan Small-Molecule New Drug Innovation Alliance, the SUSTech Pingshan Institute of Biomedicine, and the Department of Chemistry at the Southern University of Science and Technology (SUSTech), the conference balances academic expertise with industrial application. It covers the entire pharmaceutical value chain, including R&D, manufacturing, process innovation, and compliant global market expansion. The main forum is held in the Bougainvillea Hall on the 5th floor of the Shenzhen Convention & Exhibition Center. Concurrent specialized sessions-including the Greater Bay Area Pharmaceutical Industry "Industry 4.0" Forum, the Forum on Compliance and Control in Large-Scale Pharmaceutical Production, and the Seminar on Pharmaceutical Industry Global Expansion-address key industry pain points and cutting-edge trends from multiple perspectives.
As a core foundation of the pharmaceutical industry, Active Pharmaceutical Ingredients (APIs) are a key focus of the conference discussions. Guest speakers are sharing in-depth insights on critical topics such as the green transformation of the domestic API industry, process optimization, quality system upgrades, and compliant cross-border exports. Addressing the current landscape of the active pharmaceutical ingredient (API) industry-characterized by homogenized competition, mounting environmental pressures, and rising barriers related to international certification-the expert team provided in-depth insights into implementing green chemistry in API synthesis and upgrading to continuous manufacturing processes. They also analyzed the latest domestic and international pharmacopoeia standards and export regulations. These efforts offered actionable technical solutions and strategic guidance to help API enterprises reduce costs, enhance efficiency, ensure regulatory compliance, and expand into overseas markets, thereby facilitating the industry's transition from mere scale expansion to a focus on quality innovation and high-end customization.
Innovation in high-end pharmaceutical formulations is a key driver for the industry's quality upgrade and a major topic of discussion at the conference. Industry leaders focused on sectors such as peptide drugs, oligonucleotide therapeutics, sustained/controlled-release formulations, and targeted drug delivery systems. They conducted in-depth analyses of R&D challenges, key industrialization technologies, and efficacy and safety evaluation frameworks for novel formulations. Leveraging the Greater Bay Area's strengths in new drug R&D, participants shared practical experiences regarding process innovation, end-to-end quality traceability, and large-scale production. These discussions aimed to resolve industry-wide hurdles-such as low R&D-to-commercialization conversion rates, high industrialization costs, and stability issues-thereby accelerating the transition of innovative formulation technologies from laboratory research to clinical application and market launch.
As a cutting-edge technology poised to revolutionize the pharmaceutical industry, synthetic biology emerged as a central highlight of the conference. The event fostered deep collaboration between the fields of natural product synthesis and advanced pharmaceutical manufacturing, focusing on innovative applications of synthetic biology in areas such as natural drug synthesis, green API production, novel drug target discovery, and CMC (Chemistry, Manufacturing, and Controls) development for biopharmaceuticals. Experts shared breakthroughs in technologies such as strain engineering, biocatalysis, and efficient synthesis pathway design. They demonstrated how synthetic biology is reshaping pharmaceutical production models by drastically reducing pollution from chemical synthesis and enhancing both efficiency and purity. This offers a new technological pathway for the industry to achieve low-carbon, intelligent, and precision-oriented development, while unlocking new frontiers for pharmaceutical innovation.
In addition to sharing core technical insights, the conference also focused on the digital and intelligent transformation of the pharmaceutical industry and the promotion of collaborative industrial development. Multiple parallel forums featured in-depth discussions on hot topics such as the construction of intelligent pharmaceutical manufacturing systems, the practical application of AI in drug development, the growth of the pharmaceutical CXO sector, end-to-end compliance management, and opportunities for Greater Bay Area pharmaceutical companies to expand globally. These sessions directly addressed the core needs of pharmaceutical enterprises regarding digital transformation, compliant operations, and international expansion. Furthermore, the conference brought together over a hundred domestic and international pharmaceutical companies, research institutions, and investment firms, establishing a premier platform for technology matchmaking, the commercialization of research findings, industry collaboration, and resource sharing, thereby effectively fostering the deep integration of industry, academia, research, and application.
The CPHI Shenzhen Conference on High-Quality Pharmaceutical Development is designed to synergize with the CPHI & PMEC Shenzhen pharmaceutical industry exhibition series (held from September 16 to 18), ensuring a continuous flow of cutting-edge insights across the entire industry value chain. Industry experts noted that by leveraging the strengths of the Greater Bay Area's biopharmaceutical cluster and aligning with global innovation trends, the conference showcases cutting-edge technologies, practical expertise, and industry solutions. These elements will effectively empower domestic pharmaceutical companies to overcome technical bottlenecks, refine their industrial systems, and seize market opportunities, ultimately propelling China's pharmaceutical industry toward high-quality development characterized by high-end capabilities, intelligence, sustainability, and global integration.
Shaanxi Lv Ke Chun Yuan Biotechnology Co., Ltd
Our address
Huaxia Yue World, Weibin District, Baoji City, Shaanxi Province
Phone Number
+86-13571783771
